Signal Chooses Acquisition By Celgene Over Initial Public Offering
Executive Summary
Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.